Current Report Filing (8-k)
May 31 2019 - 7:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): May 31, 2019 (May 30, 2019)
Protalix
BioTherapeutics, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-33357
|
|
65-0643773
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
2 Snunit Street
|
|
20100
|
Science Park, POB 455
|
|
|
Carmiel, Israel
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code +972-4-988-9488
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
|
¨
|
Written communication pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title
of each class
|
Trading
Symbol(s)
|
Name of
each exchange on which registered
|
common stock, $0.001 par value
|
PLX
|
NYSE American
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 5.07
Submission of Matters to a Vote of Security Holders
The 2019 Annual Meeting of Stockholders (the “Meeting”)
of Protalix BioTherapeutics, Inc. (the “Company”) was held on May 30, 2019. At the meeting, the Company’s stockholders:
(1) elected the six persons recommended by the Company’s Board of Directors to serve as directors of the Company; (2) approved,
on a non-binding, advisory basis, the compensation of the Company’s named executive officers; and (3) ratified the selection
of appointment of Kesselman & Kesselman, Certified Public Accountant (Isr.), a Member of PricewaterhouseCoopers International
Limited, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.
Set forth below, with respect to each such proposal, are the
number of votes cast for or against or withheld, as applicable, the number of abstentions and the number of broker non-votes.
|
(1)
|
Election of Directors
|
|
|
For
|
|
Withheld
|
|
Broker
Non-Votes
|
Shlomo Yanai
|
|
38,254,415
|
|
7,988,641
|
|
37,207,180
|
Moshe Manor
|
|
33,746,849
|
|
12,496,207
|
|
37,207,180
|
Amos Bar Shalev
|
|
38,091,209
|
|
8,151,847
|
|
37,207,180
|
Zeev Bronfeld
|
|
39,926,728
|
|
6,316,328
|
|
37,207,180
|
David Granot
|
|
41,766,533
|
|
4,476,523
|
|
37,207,180
|
Aharon Schwartz, Ph.D.
|
|
40,781,248
|
|
5,461,808
|
|
37,207,180
|
|
(2)
|
Approval, on a non-binding, advisory basis, the compensation
of the Company’s named executive officers
|
For
|
|
Against
|
|
Abstain
|
|
Broker
Non-Votes
|
32,204,147
|
|
13,720,259
|
|
318,650
|
|
37,207,180
|
|
(3)
|
Ratification of the appointment of Kesselman & Kesselman
|
For
|
|
Against
|
|
Abstain
|
80,583,750
|
|
2,236,806
|
|
629,680
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May
31, 2019
|
PROTALIX BIOTHERAPEUTICS, INC.
|
|
|
|
By:
|
/s/ Yossi
Maimon
|
|
|
Name:
|
Yossi Maimon
|
|
|
Title:
|
Vice President and Chief Financial Officer
|
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Apr 2023 to Apr 2024